Related Experiment Videos
National adverse drug reaction reporting. 1984-1989
1Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD.
Archives of Internal Medicine
|August 1, 1991
Summary
Continued reporting of adverse drug reactions to the Food and Drug Administration (FDA) is crucial for enhancing pharmaceutical safety. Increased reporting, driven by new regulations, aids in identifying potential drug risks and improving product information.
Area of Science:
- Pharmacovigilance and Drug Safety
- Regulatory Science
- Public Health
Background:
- Drug approval processes do not guarantee absolute safety.
- New safety information emerges after drugs enter clinical practice.
- Post-market surveillance is essential for ongoing drug safety assurance.
Purpose of the Study:
- To analyze trends in adverse drug reaction reporting to the Food and Drug Administration (FDA).
- To evaluate the impact of regulatory changes on reporting.
- To highlight the significance of pharmacovigilance in ensuring pharmaceutical safety.
Main Methods:
- Analysis of adverse reaction reports submitted to the FDA between 1985 and 1989.
- Examination of the sources of these reports (physicians, manufacturers).
- Assessment of report characteristics (new drugs, serious reactions).
Main Results:
- A significant increase in adverse reaction reports to the FDA from 1985-1989, totaling 261,515.
- New legal requirements for manufacturers substantially contributed to this increase.
- Most reports originated from physicians and frequently involved new drugs and serious adverse events.
Conclusions:
- Adverse reaction surveillance identifies 50-100 critical safety issues annually.
- This surveillance leads to essential updates in drug product information.
- Continued reporting by healthcare providers is vital for improving pharmaceutical safety and use.